Cost-effectiveness of different human papillomavirus vaccines in Singapore
Open Access
- 31 March 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Public Health
- Vol. 11 (1), 203-11
- https://doi.org/10.1186/1471-2458-11-203
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialBMJ, 2010
- Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in TaiwanBMC Health Services Research, 2010
- A cost–utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programmeEuropean Journal of Public Health, 2009
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Health and Economic Implications of HPV Vaccination in the United StatesNew England Journal of Medicine, 2008
- Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in SwitzerlandCurrent Medical Research and Opinion, 2008
- Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UKBritish Journal of Cancer, 2006
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006
- Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysisBritish Journal of Cancer, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003